Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Werner, Rudolf A., Lapa, Constantin, Ilhan, Harun, Higuchi, Takahiro, Buck, Andreas K., Lehner, Sebastian, Bartenstein, Peter, Bengel, Frank, Schatka, Imke, Muegge, Dirk O., Papp, László, Zsótér, Norbert, Große-Ophoff, Tobias, Essler, Markus, Bundschuh, Ralph A.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351689/
https://ncbi.nlm.nih.gov/pubmed/27705948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12402
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars